Dr. Cummings is an Internal Medicine specialist and Professor of Medicine, Epidemiology, and Biostatistics at UC San Francisco. He is the Executive Director of the San Francisco Coordinating Center in the California Pacific Medical Center Research Institute. He is an internationally recognized expert on osteoporosis and prevention of fractures. He has led the large clinical trials that won FDA approval for most of the drug treatments for osteoporosis – Alendronate, Zoledronate, Denosumab, and Raloxifene. He has designed and led large longitudinal studies about risk factors for osteoporosis, including the Study of Osteoporotic Fractures for older women and MrOS for older men. He has published articles about the risk of fractures in patients with medical and neurolgic conditions, He has over 600 peer-reviewed publications and won several awards for his research in osteoporosis including ASBMR’s William Neuman Award for Outstanding and Major Scientific Contributions and Frederick Bartter Award for Excellence in Clinical Research in Bone and Mineral Research. He has also been elected to the prestigious National Academy of Medicine in the National Academy of Sciences for his contributions to Clinical Research.